On Wednesday, Shares of Freeport-McMoRan Inc. (NYSE:FCX), gained 2.24% to $20.56.
Freeport-McMoRan, declared a cash dividend of $0.1605 per share payable on August 3, 2015 to holders of record as of July 15, 2015 for its common stock.
The August 2015 common stock dividend comprises of $0.05 per share for FCX’s regular quarterly dividend and $0.1105 per share as a special dividend related to the formerly declared settlement of the stockholder derivative litigation approved by the Delaware Court of Chancery in April 2015.
Freeport-McMoRan Inc., a natural resource company, engages in the acquisition of mineral assets, and oil and natural gas resources. It primarily explores for copper, gold, molybdenum, cobalt, silver, and other metals, in addition to oil and gas.
Shares of AbbVie Inc. (NYSE:ABBV), declined -1.14% to $69.22, during its last trading session.
AbbVie, declared TURQUOISE-III study results demonstrating 100 percent (n=60/60) sustained virologic response at 12 weeks post-treatment (SVR12) in genotype 1b (GT1b) chronic hepatitis C virus (HCV) infected adult patients with compensated liver cirrhosis.1 Patients received 12 weeks of VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) without ribavirin (RBV). These new results from AbbVie’s Phase 3b study will be presented at the 15th Annual International Symposium on Viral Hepatitis and Liver Diseases in Berlin, Germany.
About 160 million people worldwide are infected with HCV. Genotype 1 is the most common type of HCV genotype, accounting for 60 percent of cases worldwide and in Europe, the most prevalent genotype is 1b (47 percent). Over time, chronic HCV may lead to liver complications, counting compensated cirrhosis, in about 10-20 percent of people infected.
Patients in TURQUOISE-III were either treatment-naïve or treatment-practiced (failed previous therapy with pegylated interferon and RBV). No patients suspended treatment due to adverse events. The most commonly stated adverse events (>10 percent) were fatigue (22 percent), diarrhea (20 percent) and headache (18 percent).
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company’s products comprise HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; VIEKIRA PAK, an all-oral, short-course, interferon-free therapy, with or without ribavirin, for adult patients with genotype 1 chronic hepatitis, counting those with compensated cirrhosis; Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1 infection; and Synagis to prevent respiratory syncytial virus infection in high risk infants.
Finally, Suncor Energy Inc. (NYSE:SU), ended its last trade with 2.17% gain, and closed at $28.78, as oil futures settled lower on Wednesday after a weekly U.S. government report revealed an unpredictable climb in gasoline supplies and an enhance in oil production.
August crude lost 74 cents, or 1.2%, to settle at $60.27 a barrel on the New York Mercantile Exchange following a volatile session in the wake of supply data.
Oil held above $64 a barrel on Wednesday as a U.S. government report showing crude inventories fell for an eighth week, in a sign a supply glut is easing, countered concerns about Greece’s debt crisis.
U.S. crude stocks fell by 4.9 million barrels, the U.S. Energy Information Administration (EIA) said, more than analysts predictable. This confirmed a trend stated by the industry group American Petroleum Institute on Tuesday.
Suncor Energy Inc. operates as an integrated energy company. The company primarily focuses on developing petroleum resource basins in Canada’s Athabasca oil sands; explores, acquires, develops, produces, and markets crude oil and natural gas in Canada and internationally; transports and refines crude oil; markets petroleum and petrochemical products primarily in Canada; and markets third party petroleum products.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
